sotatercept – Medxy AI

Sotatercept as Add-On Therapy in Pediatric Pulmonary Hypertension: Promising Outcomes from the Pediatric Pulmonary Hypertension Network

By MedXY 10/11/2026

Retrospective multi-center data demonstrate that sotatercept improves functional status, exercise capacity, and hemodynamics in children with pulmonary hypertension, with a manageable safety profile.

Cardiology news

Sotatercept Enhances Right Heart Function by Optimizing Mechanics in Pulmonary Arterial Hypertension

By MedXY 09/25/2026

Sotatercept improves right heart mechanics in patients with pulmonary arterial hypertension by decreasing right ventricular afterload and contractility in a balanced manner, enhancing right ventricular free wall function and right atrial performance without compromising ventricular-arterial coupling.

Cardiology news Respiratory

Sotatercept’s Multifaceted Role in Enhancing Exercise Capacity in Pulmonary Arterial Hypertension

By MedXY 08/12/2026

Sotatercept improves exercise tolerance in pulmonary arterial hypertension through pulmonary vascular remodeling, systemic decongestion with hemoconcentration, improved right ventricular-pulmonary artery coupling, enhanced cardiac output reserve, and increased peripheral oxygen utilization.

Cardiology news Respiratory

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

By MedXY 10/25/2025

This article reviews a phase 3 trial analyzing sotatercept's efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

Clinical Updates news Respiratory Specialties

Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

By MedXY 08/02/2025

Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.